GR1006896B - Μεθοδος παραγωγης μιας πεπτιδικης ορμονης - Google Patents

Μεθοδος παραγωγης μιας πεπτιδικης ορμονης

Info

Publication number
GR1006896B
GR1006896B GR20070100553A GR20070100553A GR1006896B GR 1006896 B GR1006896 B GR 1006896B GR 20070100553 A GR20070100553 A GR 20070100553A GR 20070100553 A GR20070100553 A GR 20070100553A GR 1006896 B GR1006896 B GR 1006896B
Authority
GR
Greece
Prior art keywords
producing
peptide hormone
hepcidin
novel
provides
Prior art date
Application number
GR20070100553A
Other languages
English (en)
Other versions
GR20070100553A (el
Inventor
Αυγη Μαμαλακη
Βασιλικη Κολιαρακη
Μαρθα Μαρινου
Original Assignee
Ελληνικο Ινστιτουτο Παστερ,
Αυγη Μαμαλακη
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ελληνικο Ινστιτουτο Παστερ,, Αυγη Μαμαλακη filed Critical Ελληνικο Ινστιτουτο Παστερ,
Priority to GR20070100553A priority Critical patent/GR1006896B/el
Priority to PCT/GR2008/000056 priority patent/WO2009027752A2/en
Priority to AU2008291842A priority patent/AU2008291842A1/en
Priority to JP2010521489A priority patent/JP2010536364A/ja
Priority to EP08788798A priority patent/EP2195339A2/en
Priority to CA2697976A priority patent/CA2697976A1/en
Priority to US12/675,007 priority patent/US8614068B2/en
Priority to KR1020107006382A priority patent/KR20100065335A/ko
Publication of GR20070100553A publication Critical patent/GR20070100553A/el
Publication of GR1006896B publication Critical patent/GR1006896B/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag

Abstract

Η παρούσα εφεύρεση παρέχει μια καινοτόμο μέθοδο για παραγωγή βιολογικά λειτουργικής εψιδίνης. Η εφεύρεση παρέχει νέα σημασμένη εψιδίνη, αντισώματα και τη χρήση τους στην θεραπεία και σε ανοσοδοκιμασίες.
GR20070100553A 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης GR1006896B (el)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GR20070100553A GR1006896B (el) 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
PCT/GR2008/000056 WO2009027752A2 (en) 2007-08-24 2008-08-22 Process for producing hepcidin
AU2008291842A AU2008291842A1 (en) 2007-08-24 2008-08-22 Process for producing hepcidin
JP2010521489A JP2010536364A (ja) 2007-08-24 2008-08-22 ペプチドホルモンの生成工程
EP08788798A EP2195339A2 (en) 2007-08-24 2008-08-22 A process for producing hepcidin
CA2697976A CA2697976A1 (en) 2007-08-24 2008-08-22 A process for producing a peptide hormone
US12/675,007 US8614068B2 (en) 2007-08-24 2008-08-22 Process for producing hepcidin
KR1020107006382A KR20100065335A (ko) 2007-08-24 2008-08-22 헵시딘을 제조하는 방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20070100553A GR1006896B (el) 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης

Publications (2)

Publication Number Publication Date
GR20070100553A GR20070100553A (el) 2009-03-17
GR1006896B true GR1006896B (el) 2010-07-20

Family

ID=40219993

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20070100553A GR1006896B (el) 2007-08-24 2007-08-24 Μεθοδος παραγωγης μιας πεπτιδικης ορμονης

Country Status (8)

Country Link
US (1) US8614068B2 (el)
EP (1) EP2195339A2 (el)
JP (1) JP2010536364A (el)
KR (1) KR20100065335A (el)
AU (1) AU2008291842A1 (el)
CA (1) CA2697976A1 (el)
GR (1) GR1006896B (el)
WO (1) WO2009027752A2 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462307B1 (ko) 2008-08-06 2014-11-17 일라이 릴리 앤드 캄파니 항-헵시딘-25 선택적 항체 및 그의 용도
CN102574805A (zh) 2009-08-20 2012-07-11 维福(国际)股份公司 新型喹啉铁调素拮抗剂
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
EP2475643A1 (de) 2009-09-07 2012-07-18 Vifor (International) Ag Neue ethandiamin-hepcidin-antagonisten
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
HUE057168T2 (hu) 2013-03-15 2022-04-28 Protagonist Therapeutics Inc A hepcidin analógjai és ezek alkalmazása
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3432906A4 (en) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
US11834696B2 (en) * 2017-04-05 2023-12-05 Arizona Board Of Regents On Behalf Of Arizona State University Antimicrobial susceptibility testing with large-volume light scattering imaging and deep learning video microscopy
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN109593766A (zh) * 2018-12-11 2019-04-09 武汉大北农水产科技有限公司 草鱼铁调素基因及其编码的重组蛋白和应用
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin

Also Published As

Publication number Publication date
CA2697976A1 (en) 2009-03-05
EP2195339A2 (en) 2010-06-16
WO2009027752A2 (en) 2009-03-05
AU2008291842A1 (en) 2009-03-05
US20110097749A1 (en) 2011-04-28
KR20100065335A (ko) 2010-06-16
US8614068B2 (en) 2013-12-24
JP2010536364A (ja) 2010-12-02
WO2009027752A3 (en) 2009-06-11
GR20070100553A (el) 2009-03-17

Similar Documents

Publication Publication Date Title
GR1006896B (el) Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
MY171841A (en) Antibody formulation
EP1814586A4 (en) ANTI-PROPERDINE ANTIBODY AND METHOD OF MANUFACTURING AND USING THE SAME
SG162728A1 (en) Tweak binding antibodies
TW200738270A (en) Method of treating depression using a TNFα antibody
PE20150222A1 (es) Anticuerpos multiespecificos
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
WO2010145792A8 (en) Bispecific antigen binding proteins
HRP20120606T1 (en) Anti-il-17 antibodies
SG166091A1 (en) Method for producing isocyanates
WO2009004822A1 (ja) 抗Muc17抗体
TW200636064A (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
MY183144A (en) Toll-like receptor 3 antagonists
WO2010079510A3 (en) Anti-rhd monoclonal antibodies
EP1731032A4 (en) NON-HUMAN ANIMAL FOR CONSTRUCTING ANTIBODY, AND METHOD AND SYSTEM FOR CONSTRUCTING ANTIBODY USING THE SAME
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
EP1700122A4 (en) IMMUNOASSAYS, HAPTENE, IMMUNOGENES AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
EP1799252A4 (en) ANTIBODY PRODUCTION PROCESS
UA91683C2 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ZA200804337B (en) Recombinant monovalent antibodies and methods for production thereof

Legal Events

Date Code Title Description
PG Patent granted